Last reviewed · How we verify
SHR2554 analog tablets; Chidamide
Chidamide is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and the activation of tumor suppressor genes.
Chidamide is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and the activation of tumor suppressor genes. Used for Relapsed or refractory peripheral T-cell lymphoma, Relapsed or refractory cutaneous T-cell lymphoma.
At a glance
| Generic name | SHR2554 analog tablets; Chidamide |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Histone deacetylase inhibitor |
| Target | Histone deacetylases |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This results in the inhibition of cell proliferation and the induction of apoptosis in cancer cells. Chidamide also has immunomodulatory effects, enhancing the activity of immune cells and promoting an anti-tumor immune response.
Approved indications
- Relapsed or refractory peripheral T-cell lymphoma
- Relapsed or refractory cutaneous T-cell lymphoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Anemia
- Thrombocytopenia
- Neutropenia
- Leukopenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: